Guangzhou Wanfangjian Medicine Co.,Ltd – Trademark Portfolio
Entity Type: 16
Guangzhou Wanfangjian Medicine Co.,Ltd has 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO). Notable registered marks include ZIOXX. The portfolio includes 1 registered trademark and 2 pending applications. Filings span 3 Nice Classification classes, led by Class 10 (Medical Apparatus) and Class 5 (Pharmaceuticals). This trademark owner is based in Guangzhou.
No.3,Jinfengyuan Rd, Science City
51067
Guangzhou 510000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Guangzhou Wanfangjian Medicine Co.,Ltd's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Raw and unprocessed agricultural, aquacultural, horticultural and forestry products
Frequently Asked Questions
How many trademarks does Guangzhou Wanfangjian Medicine Co.,Ltd have?
Guangzhou Wanfangjian Medicine Co.,Ltd has 5 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 pending, 2 abandoned.
What trademark classes does Guangzhou Wanfangjian Medicine Co.,Ltd file in?
Guangzhou Wanfangjian Medicine Co.,Ltd files trademarks across 3 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals), Class 31 (Natural Agricultural Products). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Guangzhou Wanfangjian Medicine Co.,Ltd's most well-known trademarks?
Guangzhou Wanfangjian Medicine Co.,Ltd's registered trademark portfolio includes well-known marks such as ZIOXX. These are among 1 currently registered trademark in the portfolio.
What is Guangzhou Wanfangjian Medicine Co.,Ltd's trademark registration success rate?
Guangzhou Wanfangjian Medicine Co.,Ltd has a 33% trademark registration rate, with 1 out of 3 resolved applications resulting in successful registration. Currently, 2 applications are pending review.